Specify a stock or a cryptocurrency in the search bar to get a summary
Organovo Holdings Inc
ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121
Analytics
WallStreet Target Price
6.1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ONVO
Dividend Analytics ONVO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ONVO
Stock Valuation ONVO
Financials ONVO
Results | 2019 | Dynamics |